加载中
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
收盘时
US$1.62
−US$0.01 · -0.61%
盘后
US$1.6493
+US$0.0293 · +1.81%
10月12日 19:02 ET
盘中时间采用ET。市场数据可能有所延迟。
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
日内区间
当前US$1.62
52周区间
当前US$1.62
盘中时间采用ET。市场数据可能有所延迟。
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
日内区间
当前US$1.62
52周区间
当前US$1.62
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1527.82万 EUR | 1890.5万 EUR | 651.4万 EUR | 359.4万 EUR | 133.5万 EUR |
| 销货成本 | 259.63万 EUR | — | — | — | — |
| 毛利 | 1268.19万 EUR | 1890.5万 EUR | 651.4万 EUR | 359.4万 EUR | 133.5万 EUR |
| 研究与开发 | 4071.79万 EUR | 3635.6万 EUR | 2514.8万 EUR | 5086.7万 EUR | 4222万 EUR |
| 销售、一般及管理费用 | 1506万 EUR | 1366.1万 EUR | 1623.6万 EUR | 1865.1万 EUR | 1736.8万 EUR |
| 营业费用 | 5483.68万 EUR | 4937.7万 EUR | 3837.3万 EUR | 6875.3万 EUR | 5854.5万 EUR |
| 利息收入 | 224.09万 EUR | 325.1万 EUR | 259.3万 EUR | 10.6万 EUR | 5000 EUR |
| 利息支出 | 86.64万 EUR | 107.7万 EUR | 120.3万 EUR | 512.7万 EUR | 340.5万 EUR |
| 折旧和摊销 | 270.3万 EUR | 276.1万 EUR | 251.3万 EUR | 252.1万 EUR | 232.9万 EUR |
| 营业利润 | −4215.49万 EUR | −3047.2万 EUR | −3185.9万 EUR | −6515.9万 EUR | −5721万 EUR |
| 净利润 | −4051.91万 EUR | −2776.3万 EUR | −2811.9万 EUR | −6442.4万 EUR | −6074万 EUR |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
